BeiGene Clinical Pipeline - Hematology

 PDF   1   09/2020

For more information about this publication, please submit a medical information request.

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service